Further, tamoxifen-mediated Smarcd3 deletion led to a ~3-fold drop in total free fatty acid content in EpCAM+ Smarcd3f/f-KPF-R26-CreERT2 tumor cells in vivo, as determined by gas chromatography–mass spectrometry (GC–MS) (Supplementary Fig. 5c). This evidence concerns the gene SMARCD3 and neoplasm.